The agreements mean the remaining claims against the Swiss maker of generic drugs in the U.S. generic antitrust litigation are those from individual plaintiffs.
Source link
About The Author
Sandoz to Pay Around $480 Million to Settle U.S. Antitrust Pricing Litigations